Search Results
Feb 25, 2026, 10:30 ET Allergy Immunotherapy Market to Reach $4.9 billion by 2033 Globally, at 10.4% CAGR: Allied Market Research
reach expansion to strengthen market positions. Leading companies prioritize the development of new and improved immunotherapy treatments. For example, ALK-Abelló has a robust pipeline with sublingual immunotherapy (SLIT) tablets and subcutaneous immunotherapy (SCIT) formulations covering grass pollen, dust
More news about: Allied Market Research
Feb 22, 2026, 19:10 ET CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
metastatic NSCLC with no sensitizing EGFR mutations, or ALK, ROS1 or RET genomic tumor aberrations; andMonotherapy for adult patients with unresectable stage III NSCLC with PD-L1 expression on ≥1% of tumour cells and no sensitising EGFR mutations, or ALK, ROS1 genomic aberrations and whose disease has
More news about: CStone Pharmaceuticals
Feb 20, 2026, 08:00 ET Zenocutuzumab Treatment Beyond Progression Demonstrates Continued Benefit in Patients with NRG1+ Non-Small Cell Lung Cancer: New Results from the eNRGy Trial
FusionsNRG1 fusions are unique cancer drivers that create oncogenic chimeric ligands rather than the more widely described chimeric receptors (NTRK, RET, ROS1, ALK, and FGFR fusions). The chimeric ligands bind to HER3, triggering HER2/HER3 heterodimerization and activate downstream signaling pathways that
More news about: Partner Therapeutics, Inc.
Feb 16, 2026, 06:45 ET Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Naarden, executive vice president and president of Lilly Oncology. "Building on the adoption of targeted therapies for early-stage patients with EGFR- and ALK-driven lung cancer, we hope these results further accelerate the use of genomic testing for all people diagnosed with early-stage disease."LIBRETTO-432
More news about: Eli Lilly and Company
Feb 12, 2026, 12:45 ET Ben Brookman promoted to Vice President of Real Estate and Airport Affairs for Alaska Airlines
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Feb 11, 2026, 08:00 ET Alaska Airlines and Hawaiian Airlines introduce spring menus featuring regional favorites and chef-led dining
Hawaiian. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Feb 11, 2026, 08:00 ET Frontier Airlines Reports Fourth Quarter 2025 Financial Results
Notes1 Industry average weighted by ASMs in each respective period and includes the following carriers: DAL, UAL, AAL, LUV, JBLU, ALK, and ALGT; adjusted CASM + net interest is stage adjusted to 1,000 miles for consistency across all carriers, calculated as adjusted CASM + net interest
More news about: Frontier Group Holdings, Inc.
Feb 05, 2026, 12:35 ET Zenocutuzumab‑zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma
fusions are unique cancer drivers that create oncogenic chimeric ligands rather than the more widely described chimeric receptors (NTRK, RET, ROS1, ALK, and FGFR fusions). The chimeric ligands bind to HER3, triggering HER2/HER3 heterodimerization and activate downstream signaling pathways that
More news about: Partner Therapeutics, Inc.
Feb 05, 2026, 06:30 ET Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
More news about: Nuvalent, Inc.
Feb 02, 2026, 17:19 ET Aloha to Big Rewards: Millions of Atmos™ Rewards Points Up for Grabs for Hawaiian Airlines World Elite Mastercard® Cardmembers in 2026
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Hawaiian Airlines
Jan 30, 2026, 08:00 ET A new home for training excellence: Alaska Airlines unveils state-of-the-art Global Training Center
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Jan 29, 2026, 13:31 ET Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
chylomicronemia syndrome, ongoing Phase 3 study of zodasiran in homozygous familial hypercholesterolemia, and Phase 1/2 studies of ARO-INHBE and ARO-ALK7 for obesity.Source:
More news about: USA News Group
Jan 28, 2026, 16:30 ET AAR celebrates Airframe MRO expansion in Oklahoma City, prepares to induct additional Alaska Airlines aircraft
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: AAR CORP.
Jan 26, 2026, 17:31 ET RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
pemetrexed, in previously treated NSCLC patients harboring EGFR exon 19 deletions or exon 21 L858R mutations, as well as other oncogenic drivers such as ALK, ROS1, BRAF V600E, NTRK, MET exon 14 skipping mutations, RET rearrangements, and uncommon EGFR variants. The study is designed to determine therapeutic
More news about: DelveInsight Business Research, LLP
Jan 22, 2026, 18:44 ET Alaska Air Group reports fourth quarter and full year 2025 results
year SEATTLE, Jan. 22, 2026 /PRNewswire/ -- Alaska Air Group Inc. (NYSE: ALK) today reported financial results for the fourth quarter and full year ended December 31, 2025.
More news about: Alaska Air Group
Jan 21, 2026, 03:07 ET Kanazawa University research: Visualizing how cancer drugs reshape proteins linked to lung cancer
therapies are designed to block specific molecules that drive tumor growth. One such molecule, ALK, plays a central role in a form of lung cancer caused by a genetic fusion known as EML4–ALK. Drugs that inhibit ALK have dramatically improved patient outcomes, but many patients eventually develop resistance,
More news about: Kanazawa University
Jan 14, 2026, 20:16 ET 亞盛醫藥精彩亮相第44屆摩根大通醫療健康年會主會場，「全球創新」戰略邁入新階段
國開展貧血相關適應症的I期臨床試驗APG-2449（FAK/ALK/ROS1抑制劑）：已進入針對非小細胞肺癌（NSCLC）的全球註冊性III期臨床研究，是公司實體瘤領域的重要突破APG-115（MDM2-p53
More news about: 亞盛醫藥
Jan 14, 2026, 17:31 ET House Dust Mite Disease Market to Exhibit Substantial Growth at a CAGR of 3.5% During the Forecast Period (2025-2034) | DelveInsight
and multidisciplinary biopsy evaluation.Current Sublingual Immunotherapy Options for Allergic Rhinitis: Currently, ODACTRA (ALK-Abelló) and ACTAIR (Stallergenes Greer) are the only available treatments that use a similar way of administration. Both products are well-established
More news about: DelveInsight Business Research, LLP
Jan 12, 2026, 13:39 ET Alaska Air Group announces webcast of fourth-quarter 2025 financial results
Hawaiian. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Air Group
Jan 12, 2026, 11:15 ET Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
improves in bone density while avoiding intolerable adverse effects.Taldefgrobep-myostatin complexes also result in the inhibition of Activin E - ALK7 in adipocytes, thereby having a direct effect on reducing adipose tissue.Taldefgrobep has demonstrated a highly favorable safety and tolerability
More news about: Biohaven Ltd.
Jan 12, 2026, 06:30 ET Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
investigational, brain-penetrant, ALK-selective inhibitor created with the aim to overcome limitations observed with currently available ALK inhibitors. Neladalkib is designed to remain active in tumors that have developed resistance to first-, second-, and third-generation ALK inhibitors, including tumors
More news about: Nuvalent, Inc.
Jan 09, 2026, 10:00 ET Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma: New Results from the eNRGy Trial Presented at ASCO GI
FusionsNRG1 fusions are unique cancer drivers that create oncogenic chimeric ligands rather than the more widely described chimeric receptors (NTRK, RET, ROS1, ALK, and FGFR fusions). The chimeric ligands bind to HER3, triggering HER2/HER3 heterodimerization and activate downstream signaling pathways that
More news about: Partner Therapeutics, Inc.
Jan 07, 2026, 09:00 ET Alaska Airlines announces largest fleet order in airline's history
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Jan 05, 2026, 14:00 ET Hawaiian Airlines, a part of Alaska Airlines, announces Kahu'ewai Hawai'i Investment Plan of more than $600M over five years to modernize infrastructure and guest experience, and deepen its commitment to the community and sustainability
Learn more about what's happening at Alaska and Hawaiian at news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Hawaiian Airlines
Jan 05, 2026, 04:27 ET Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
or metastatic non-small cell lung cancer (NSCLC) who have PD-L1 tumor proportion score (TPS)≥1% and are EGFR-negative and ALK-negative.
More news about: Kelun-Biotech